SCHEMBL18038969

SCHEMBL18038969

CCN(CC)S(=O)(=O)c1ccc(=O)n(CC(=O)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 1/20 0.44
▸ HTT P42858 7/20 0.43
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ LMNA P02545 4/20 0.43
▸ USP2 O75604 1/20 0.43
▸ GAA P10253 4/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ OPRD1 P41143 1/20 0.39
▸ P2RY14 Q15391 1/20 0.39
▸ XBP1 P17861 1/20 0.39
▸ PAX8 Q06710 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18039013 0.90 SMN1; SMN2 (0.48) PTGDR2HTTSMN1; SMN2LMNAUSP2
SCHEMBL18039019 0.86 LMNA (0.53) HTTSMN1; SMN2LMNAGAAMAPT
SCHEMBL18038966 0.79 HTT (0.52) HTTSMN1; SMN2LMNAGAAL3MBTL1
SCHEMBL18038982 0.78 HTT (0.52) HTTLMNAGAAL3MBTL1KDM4E
SCHEMBL18038984 0.73 HTT (0.48) HTTSMN1; SMN2LMNAGAAL3MBTL1
SCHEMBL28035458 0.72 HTT (0.63) PTGDR2HTTSMN1; SMN2LMNAGAA
SCHEMBL18038997 0.71 LMNA (0.52) HTTSMN1; SMN2LMNAGAAL3MBTL1
SCHEMBL18038967 0.71 GAA (0.47) HTTSMN1; SMN2LMNAGAAL3MBTL1
SCHEMBL30207105 0.71 GAA (0.47) HTTSMN1; SMN2LMNAGAAL3MBTL1
SCHEMBL18038998 0.70 GAA (0.46) HTTSMN1; SMN2LMNAGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 PTGDR2 1410/4885HTT 4729/4885SMN1; SMN2 2842/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 PTGDR2 1429/4885HTT 4697/4885SMN1; SMN2 2818/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 PTGDR2 1410/4885HTT 4729/4885SMN1; SMN2 2842/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 PTGDR2 1429/4885HTT 4697/4885SMN1; SMN2 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback